相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。RNA toxicity in non-coding repeat expansion disorders
Bart Swinnen et al.
EMBO JOURNAL (2020)
Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides
Hannah Pendergraff et al.
NUCLEIC ACID THERAPEUTICS (2020)
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study
Bruce E. Sands et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Mammalian RNA Decay Pathways Are Highly Specialized and Widely Linked to Translation
Alex Charles Tuck et al.
MOLECULAR CELL (2020)
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Diane E. Frank et al.
NEUROLOGY (2020)
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides
Michael E. Ostergaard et al.
NUCLEIC ACIDS RESEARCH (2020)
Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia
PadmaKumar Narayanan et al.
NUCLEIC ACID THERAPEUTICS (2020)
Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care
Marco Luigetti et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)
Origins of the Increased Affinity of Phosphorothioate-Modified Therapeutic Nucleic Acids for Proteins
Malwina Hyjek-Skladanowska et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Phosphorothioate modified oligonucleotide-protein interactions
Stanley T. Crooke et al.
NUCLEIC ACIDS RESEARCH (2020)
Gapmer Antisense Oligonucleotides Targeting 5S Ribosomal RNA Can Reduce Mature 5S Ribosomal RNA by Two Mechanisms
Adam J. Pollak et al.
NUCLEIC ACID THERAPEUTICS (2020)
Significant Quality of Life Improvement Observed in a Patient With FCS Associated With a Marked Reduction in Triglycerides
Ioanna Gouni-Berthold
JOURNAL OF THE ENDOCRINE SOCIETY (2020)
Antisense oligonucleotide targeting of mRNAs encoding ENaC subunits α, β, and γ improves cystic fibrosis-like disease in mice
Chenguang Zhao et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Regulation of microRNA function in animals
Luca F. R. Gebert et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Entering the Modern Era of Gene Therapy
Xavier M. Anguela et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Therapeutic Antisense Oligonucleotides Are Coming of Age
C. Frank Bennett
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy
Erin S. Morgan et al.
DIABETES CARE (2019)
Experimental therapies targeting apolipoprotein C-III for the treatment of hyperlipidemia - spotlight on volanesorsen
Dimitrios Milonas et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
The current state and future directions of RNAi-based therapeutics
Ryan L. Setten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Safety evaluation of 2-deoxy-2-fluoro nucleotides in GalNAc-siRNA conjugates
Maja M. Janas et al.
NUCLEIC ACIDS RESEARCH (2019)
IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production
Jason D. Ferrone et al.
NUCLEIC ACID THERAPEUTICS (2019)
RNAi therapeutic and its innovative biotechnological evolution
Yuhua Weng et al.
BIOTECHNOLOGY ADVANCES (2019)
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
Veronica J. Alexander et al.
EUROPEAN HEART JOURNAL (2019)
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index
Wen Shen et al.
NATURE BIOTECHNOLOGY (2019)
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates
Michael E. Ostergaard et al.
NUCLEIC ACIDS RESEARCH (2019)
Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins
Michael T. Migawa et al.
NUCLEIC ACIDS RESEARCH (2019)
Current Development of siRNA Bioconjugates: From Research to the Clinic
Ivan Chernikov et al.
FRONTIERS IN PHARMACOLOGY (2019)
Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
C. Frank Bennett et al.
Annual Review of Neuroscience (2019)
Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy
Lindsay N. Alfano et al.
MEDICINE (2019)
Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models
Youngsoo Kim et al.
MOLECULAR THERAPY (2019)
Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2019)
mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2019)
Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells
Shiyu Wang et al.
NUCLEIC ACID THERAPEUTICS (2019)
Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis
Morie A. Gertz et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
Basil T. Darras et al.
CNS DRUGS (2019)
Phase 1 Investigation of a Ligand-Conjugated Antisense Oligonucleotide with Increased Potency for the Treatment of Transthyretin Amyloidosis
Nicholas J. Viney et al.
JOURNAL OF CARDIAC FAILURE (2019)
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Darryl C. De Vivo et al.
NEUROMUSCULAR DISORDERS (2019)
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
J. L. Witztum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: results from a phase 1 clinical trial
K. Wagner et al.
NEUROMUSCULAR DISORDERS (2019)
Kinetic and subcellular analysis of PS-ASO/protein interactions with P54nrb and RNase H1
Timothy A. Vickers et al.
NUCLEIC ACIDS RESEARCH (2019)
Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma
Xiangjun Tang et al.
FRONTIERS IN ONCOLOGY (2019)
Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2019)
Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
Navid Khan et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2019)
Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs
Xue-Hai Liang et al.
NUCLEIC ACIDS RESEARCH (2018)
Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes
Andres Digenio et al.
DIABETES CARE (2018)
Locked nucleic acid: modality, diversity, and drug discovery
Peter H. Hagedorn et al.
DRUG DISCOVERY TODAY (2018)
A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly
Peter J. Trainer et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study
Dirk J. Blom et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Advanced siRNA Designs Further Improve In Vivo Performance of GaINAc-siRNA Conjugates
Donald J. Foster et al.
MOLECULAR THERAPY (2018)
Eteplirsen treatment for Duchenne muscular dystrophy Exon skipping and dystrophin production
Jay S. Charleston et al.
NEUROLOGY (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Acute hepatotoxicity of 2′ fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins
Wen Shen et al.
NUCLEIC ACIDS RESEARCH (2018)
The Effects of 2-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2018)
Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Do Not
R. L. Juliano
NUCLEIC ACID THERAPEUTICS (2018)
GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
Aaron D. Springer et al.
NUCLEIC ACID THERAPEUTICS (2018)
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
C. Ammala et al.
SCIENCE ADVANCES (2018)
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Matthew J. Reilley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
A Placebo-controlled Study of PF-06473871 (Anti-Connective Tissue Growth Factor Antisense Oligonucleotide) in Reducing Hypertrophic Skin Scarring
Jeremy D. Gale et al.
PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN (2018)
Alicaforsen for the treatment of inflammatory bowel disease
Vipul Jairath et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Alicaforsen in the treatment of pouchitis
Thomas Greuter et al.
IMMUNOTHERAPY (2017)
RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions
A. Robert MacLeod et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus
Xue-Hai Liang et al.
MOLECULAR THERAPY (2017)
Cellular uptake and trafficking of antisense oligonucleotides
Stanley T. Crooke et al.
NATURE BIOTECHNOLOGY (2017)
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Mark J. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The impact of base stacking on the conformations and electrostatics of single-stranded DNA
Alex Plumridge et al.
NUCLEIC ACIDS RESEARCH (2017)
5′-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo
Reka A. Haraszti et al.
NUCLEIC ACIDS RESEARCH (2017)
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates
Jayaprakash K. Nair et al.
NUCLEIC ACIDS RESEARCH (2017)
Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2017)
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
Sarah J. Ross et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Eteplirsen in the treatment of Duchenne muscular dystrophy
Kenji Rowel Q. Lim et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2017)
First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2),in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Norbert Pfeiffer et al.
PLOS ONE (2017)
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
K. N. Chi et al.
ANNALS OF ONCOLOGY (2016)
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Andres Digenio et al.
DIABETES CARE (2016)
A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)
S. Chowdhury et al.
EUROPEAN JOURNAL OF CANCER (2016)
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Richard S. Finkel et al.
LANCET (2016)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
Modern Management of Familial Hypercholesterolemia
P. Barton Duell et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2016)
Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers
Stanley T. Crooke et al.
MOLECULAR THERAPY (2016)
Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames
Xue-hai Liang et al.
NATURE BIOTECHNOLOGY (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Viable RNaseH1 knockout mice show RNaseH1 is essential for R loop processing, mitochondrial and liver function
Walt F. Lima et al.
NUCLEIC ACIDS RESEARCH (2016)
Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity
Xue-Hai Liang et al.
NUCLEIC ACIDS RESEARCH (2016)
RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery
Walt F. Lima et al.
NUCLEIC ACIDS RESEARCH (2016)
Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
Nathalie M. Goemans et al.
PLOS ONE (2016)
Renal Effects of Antisense-Mediated Inhibition of SGLT2
Leonie van Meer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Richard S. Geary et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Mipomersen preferentially reduces small Low-density lipoprotein particle number in patients with hypercholesterolemia
Raul D. Santos et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
Sotirios Tsimikas et al.
LANCET (2015)
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease
Brett W. C. Kennedy
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2015)
The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA
Timothy A. Vickers et al.
NUCLEIC ACIDS RESEARCH (2015)
2′-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF
Wen Shen et al.
NUCLEIC ACIDS RESEARCH (2015)
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
David Hong et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Stereochemical bias introduced during RNA synthesis modulates the activity of phosphorothioate siRNAs
Hartmut Jahns et al.
NATURE COMMUNICATIONS (2015)
Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients
Meike H. van der Ree et al.
ANTIVIRAL RESEARCH (2014)
The effects of mipomersen, a second-generation antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia
Mary P. McGowan et al.
CLINICAL LIPIDOLOGY (2014)
From single-cell to cell-pool transcriptomes: Stochasticity in gene expression and RNA splicing
Georgi K. Marinov et al.
GENOME RESEARCH (2014)
Local and systemic tolerability of a 2′O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey
Robert A. Fey et al.
INHALATION TOXICOLOGY (2014)
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
Thomas Voit et al.
LANCET NEUROLOGY (2014)
CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS
Volker Limmroth et al.
NEUROLOGY (2014)
Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides
Amanda J. Ward et al.
NUCLEIC ACIDS RESEARCH (2014)
Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
W. Brad Wan et al.
NUCLEIC ACIDS RESEARCH (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
The Roles of Individual Mammalian Argonautes in RNA Interference In Vivo
Vera M. Ruda et al.
PLOS ONE (2014)
Defining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides
Walt F. Lima et al.
PLOS ONE (2014)
Antisense Oligonucleotides Capable of Promoting Specific Target mRNA Reduction via Competing RNase H1-Dependent and Independent Mechanisms
Timothy A. Vickers et al.
PLOS ONE (2014)
Targeting of Repeated Sequences Unique to a Gene Results in Significant Increases in Antisense Oligonucleotide Potency
Timothy A. Vickers et al.
PLOS ONE (2014)
Target Gene Abundance Contributes to the Efficiency of siRNA-Mediated Gene Silencing
Sun Woo Hong et al.
NUCLEIC ACID THERAPEUTICS (2014)
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic
Pedro M. D. Moreno et al.
FRONTIERS IN CHEMISTRY (2014)
Eteplirsen for the Treatment of Duchenne Muscular Dystrophy
Jerry R. Mendell et al.
ANNALS OF NEUROLOGY (2013)
Transfection of siRNAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells
Xue-hai Liang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2013)
RNA helicase A is not required for RISC activity
Xue-hai Liang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2013)
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
D. Bianchini et al.
BRITISH JOURNAL OF CANCER (2013)
Antisense Oligonucleotides: Rising Stars in Eliminating RNA Toxicity in Myotonic Dystrophy
Zhihua Gao et al.
HUMAN GENE THERAPY (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study (vol 12, pg 435, 2013)
T. M. Miller et al.
LANCET NEUROLOGY (2013)
Treatment of HCV Infection by Targeting MicroRNA
Harry L. A. Janssen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Human RNase H1 Is Associated with Protein P32 and Is Involved in Mitochondrial Pre-rRNA Processing
Hongjiang Wu et al.
PLOS ONE (2013)
Targeting RNA splicing for disease therapy
Mallory A. Havens et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2013)
Comparison between the Repression Potency of siRNA Targeting the Coding Region and the 3′-Untranslated Region of mRNA
Ching-Fang Lai et al.
BIOMED RESEARCH INTERNATIONAL (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
Timothy M. Miller et al.
LANCET NEUROLOGY (2013)
Argonaute Divides Its RNA Guide into Domains with Distinct Functions and RNA-Binding Properties
Liang Meng Wee et al.
CELL (2012)
Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression
Dongbo Yu et al.
CELL (2012)
Single-Stranded siRNAs Activate RNAi in Animals
Walt F. Lima et al.
CELL (2012)
DSIR: Assessing the Design of Highly Potent siRNA by Testing a Set of Cancer-Relevant Target Genes
Odile Filhol et al.
PLOS ONE (2012)
Unique Gene-Silencing and Structural Properties of 2 '-Fluoro-Modified siRNAs
Muthiah Manoharan et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2011)
Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy
Frederick J. Raal et al.
CIRCULATION (2011)
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
Fred Saad et al.
CLINICAL CANCER RESEARCH (2011)
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
Sebahattin Cirak et al.
LANCET (2011)
Locked Nucleic Acids: Promising Nucleic Acid Analogs for Therapeutic Applications
Rakesh N. Veedu et al.
CHEMISTRY & BIODIVERSITY (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
Antisense oligonucleotide pharmacokinetics and metabolism
Richard S. Geary
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs
Aly A. Khan et al.
NATURE BIOTECHNOLOGY (2009)
Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 'Slicer' independent and can be mediated by Ago1
Timothy A. Vickers et al.
NUCLEIC ACIDS RESEARCH (2009)
Oral delivery of antisense oligonucleotides in man
Lloyd G. Tillman et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells
Timothy A. Vickers et al.
NUCLEIC ACIDS RESEARCH (2007)
2'-O-methyl-modified RNAs act as TLR7 antagonists
Marjorie Robbins et al.
MOLECULAR THERAPY (2007)
Molecular basis for target RNA recognition and cleavage by human RISC
Stefan Ludwig Ameres et al.
CELL (2007)
Argonaute proteins: Mediators of RNA silencing
Lasse Peters et al.
MOLECULAR CELL (2007)
Interfering with disease: a progress report on siRNA-based therapeutics
Antonin de Fougerolles et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Anti-inflammatory activity of inhaled IL-4 receptor-α antisense oligonucleotide in mice
James G. Karras et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2007)
Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate
Walt F. Lima et al.
MOLECULAR PHARMACOLOGY (2007)
Widespread siRNA off-target'' transcript silencing mediated by seed region sequence complementarity
Aimee L. Jackson et al.
RNA (2006)
Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes
C Matranga et al.
CELL (2005)
Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs
HJ Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis
P Miner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis
WF Lima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Human RNase H1 uses one tryptophan and two lysines to position the enzyme at the 3′-DNA/5′-RNA terminus of the heteroduplex substrate
WF Lima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
An oxazaphospholidine approach for the stereocontrolled synthesis of oligonucleoside phosphorothioates
N Oka et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2003)
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents - A comparative analysis
TA Vickers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α
KL Sewell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide
SP Henry et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2002)
Variations in mRNA content have no effect on the potency of antisense oligonucleotides
L Miraglia et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2000)
Phosphorothioate oligodeoxynucleotides: What is their origin and what is unique about them?
F Eckstein
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2000)
分享论文
